Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 5/20 | 0.59 |
| ▸ | MAP2K1 | Q02750 | 7/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | EGFR | P00533 | 1/20 | 0.38 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.38 |
| ▸ | MMP2 | P08253 | 2/20 | 0.37 |
| ▸ | MMP13 | P45452 | 2/20 | 0.37 |
| ▸ | MMP14 | P50281 | 2/20 | 0.37 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL32663722 | 0.81 | KDR (0.63) | KDRMAP2K1EGFR | |
| SCHEMBL32664164 | 0.80 | KDR (0.49) | KDRSCN9A | |
| SCHEMBL32663847 | 0.79 | KDR (0.49) | KDRMAP2K1SCN9A | |
| SCHEMBL32664138 | 0.79 | KDR (0.47) | KDRMAP2K1EGFRERBB2 | |
| SCHEMBL32664071 | 0.78 | KDR (0.46) | KDRMAP2K1EGFRERBB2 | |
| SCHEMBL32664085 | 0.76 | KDR (0.45) | KDRSCN9A | |
| SCHEMBL32664024 | 0.75 | KDR (0.46) | KDRMAP2K1EGFRERBB2 | |
| SCHEMBL1226861 | 0.74 | KDR (1.00) | KDREGFR | |
| SCHEMBL32663848 | 0.74 | KDR (0.42) | KDRMAP2K1EGFRERBB2 | |
| SCHEMBL2502868 | 0.74 | HPGD (0.48) | KDRKDM4EALDH1A1HPGDRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260022125-A1 | PYRROLOPYRIDAZINE VEGFR INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2026-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260022125-A1 | PYRROLOPYRIDAZINE VEGFR INHIBITORS | FLT1, KDR, FLT4 | KDR 2/4885MAP2K1 624/4885KDM4E 3048/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.